About
Scientist by training, Vanessa started joined the Paris based VC fund CDC-Innovation in 1998 as an analyst, prior to joining a California based start up to be in charge of the business development activities. Vanessa then joined Ipsen in 2003, as Strategic Advisor to the CEO and headed the portfolio management team for the gastro-enterology product range (totaling more than 130M€). Vanessa was appointed in 2005 as Product Manager and Team Leader for febuxostat (Adenuric), which received EMA approval in 2008. Vanessa was then successively appointed as Senior Director, Business Development Oncology in 2009 and VP, R&D Strategic Planning in 2011. Vanessa graduated in Biology at Ecole Normale Superieure, Cachan and in Immunology at Pasteur Institute. Vanessa joined Kurma in September 2013 and is responsible for the investment in Xeltis (Switzerland), Asceneuron (Switzerland), Step Pharma (France) and Vivet (France).
Position in the VCSift Database
- • 11 investors at Kurma Partners are tracked.
- • 1,303 investors hold the Managing Partner role in VCSift. Vanessa Malier is one of them.
- • 2,833 investors are based in Paris, Ile-de-France, France.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Paris, France
Contact Information
Find more investors like Vanessa
Search Investors